NME1 and hepatocellular carcinoma: The sensitivity also increased in late-stage HCC, with the combination of ASAP/GAAD and FOXD3 showing the highest sensitivity at 95.8% with 85.7% specificity, which is slightly higher than that of the ASAP/GAAD score (91.7% sensitivity at 85.7% specificity).